Stratos Wealth Partners’s Galectin Therapeutics GALT Stock Holding History

Stratos Wealth Partners’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$88.6K	Sell	19,088 -800	-4%	-$2.07K	﹤0.01%	1667
2026 Q1	$55.5K	Buy	19,888 +800	+4%	+$2.43K	﹤0.01%	1603
2025 Q4	$79.4K	Sell	19,088 -10,962	-36%	-$57.7K	﹤0.01%	1562
2025 Q3	$127K	Sell	30,050 -30,700	-51%	-$115K	﹤0.01%	1509
2025 Q2	$128K	Buy	60,750 +9,200	+18%	+$13.8K	﹤0.01%	1372
2025 Q1	$62.9K	Hold	51,550	–	–	﹤0.01%	1335
2024 Q4	$66.5K	Buy	51,550 +11,100	+27%	+$26.6K	﹤0.01%	1416
2024 Q3	$111K	Hold	40,450	–	–	﹤0.01%	1385
2024 Q2	$91.4K	Hold	40,450	–	–	﹤0.01%	1326
2024 Q1	$96.7K	Hold	40,450	–	–	﹤0.01%	1337
2023 Q4	$67.1K	Hold	40,450	–	–	﹤0.01%	1339
2023 Q3	$77.7K	Hold	40,450	–	–	﹤0.01%	1239
2023 Q2	$58.2K	Hold	40,450	–	–	﹤0.01%	1169
2023 Q1	$84.9K	Sell	40,450 -500	-1%	-$807	﹤0.01%	1093
2022 Q4	$46.3K	Hold	40,950	–	–	﹤0.01%	1117
2022 Q3	$67K	Hold	40,950	–	–	﹤0.01%	1088
2022 Q2	$54K	Hold	40,950	–	–	﹤0.01%	1159
2022 Q1	$66K	Hold	40,950	–	–	﹤0.01%	1233
2021 Q4	$85K	Hold	40,950	–	–	﹤0.01%	1222
2021 Q3	$159K	Hold	40,950	–	–	﹤0.01%	1121
2021 Q2	$131K	Hold	40,950	–	–	﹤0.01%	1145
2021 Q1	$89K	Hold	40,950	–	–	﹤0.01%	1091
2020 Q4	$92K	Sell	40,950 -500	-1%	-$1.31K	﹤0.01%	1047
2020 Q3	$111K	Hold	41,450	–	–	﹤0.01%	965
2020 Q2	$127K	Hold	41,450	–	–	﹤0.01%	936
2020 Q1	$81K	Hold	41,450	–	–	﹤0.01%	882
2019 Q4	$119K	Hold	41,450	–	–	﹤0.01%	942
2019 Q3	$152K	Hold	41,450	–	–	0.01%	902
2019 Q2	$172K	Buy	41,450 +500	+1%	+$2.17K	0.01%	892
2019 Q1	$209K	Hold	40,950	–	–	0.01%	851
2018 Q4	$140K	Buy	40,950 +12,796	+45%	+$61.1K	0.01%	818
2018 Q3	$169K	Hold	28,154	–	–	0.01%	909
2018 Q2	$179K	Hold	28,154	–	–	0.01%	912
2018 Q1	$133K	Hold	28,154	–	–	0.01%	1057
2017 Q4	$94K	Hold	28,154	–	–	﹤0.01%	1218
2017 Q3	$60K	Buy	28,154 +4,000	+17%	+$7.93K	﹤0.01%	904
2017 Q2	$59K	Hold	24,154	–	–	﹤0.01%	814
2017 Q1	$56K	Hold	24,154	–	–	﹤0.01%	781
2016 Q4	$24K	Hold	24,154	–	–	﹤0.01%	711
2016 Q3	$27K	Buy	24,154 +5,754	+31%	+$10.2K	﹤0.01%	674
2016 Q2	$27K	Hold	18,400	–	–	﹤0.01%	619
2016 Q1	$26K	Hold	18,400	–	–	﹤0.01%	571
2015 Q4	$30K	Buy	18,400 +8,400	+84%	+$19.2K	﹤0.01%	576
2015 Q3	$23K	Sell	10,000 -1,100	-10%	-$2.59K	﹤0.01%	537
2015 Q2	$30K	Sell	11,100 -8,000	-42%	-$24.1K	﹤0.01%	519
2015 Q1	$66K	Hold	19,100	–	–	0.01%	603
2014 Q4	$66K	Hold	19,100	–	–	0.01%	495
2014 Q3	$96K	Buy	19,100 +6,200	+48%	+$48.3K	0.02%	303
2014 Q2	$180K	Buy	+12,900	New	+$161K	0.06%	295

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Stratos Wealth Partners's GALT Position: Q2 2026 in Review

Stratos Wealth Partners reduced its Galectin Therapeutics (GALT) stake by 4% in Q2 2026, selling an estimated $2.07K and leaving 19,088 shares worth $88.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1667.

Stratos Wealth Partners first reported a position in GALT in Q2 2014 and has held it in 49 quarters since. The position peaked at $209K in Q1 2019. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

Stratos Wealth Partners held 19,088 shares of Galectin Therapeutics worth $88.6K as of Q2 2026.
Stratos Wealth Partners sold 800 Galectin Therapeutics shares in Q2 2026, an estimated $2.07K.
Galectin Therapeutics made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q2 2026, its #1667 holding.
Stratos Wealth Partners first reported a position in Galectin Therapeutics in Q2 2014 and has held it in 49 quarters since.
Stratos Wealth Partners's Galectin Therapeutics position peaked at $209K in Q1 2019.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Stratos Wealth Partners's 13F filing for Q2 2026, filed 11 Aug 2026.